View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2013	Jul. 22, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	JAZZ
Entity Registrant Name	Jazz Pharmaceuticals plc
Entity Central Index Key	0001232524
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		58,153,546

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 504,307	$ 387,196
Accounts receivable, net	114,075	75,480
Inventories	28,130	26,525
Prepaid expenses	21,410	7,445
Deferred tax assets, net	46,538	35,813
Other current assets	19,716	19,113
Total current assets	734,176	551,572
Property and equipment, net	10,768	7,281
Intangible assets, net	822,976	869,952
Goodwill	439,014	442,600
Deferred tax assets, net, non-current	65,136	74,850
Deferred financing costs	16,308	16,576
Other non-current assets	5,502	3,662
Total assets	2,093,880	1,966,493
Current liabilities:
Accounts payable	20,367	15,887
Accrued liabilities	96,771	104,666
Current portion of long-term debt	5,572	29,688
Income taxes payable	17,539	39,884
Contingent consideration	42,700	0
Deferred tax liability, net	259	275
Deferred revenue	1,138	1,138
Total current liabilities	184,346	191,538
Deferred revenue, non-current	6,283	6,776
Long-term debt, less current portion	546,724	427,073
Contingent consideration, non-current	0	34,800
Deferred tax liability, net, non-current	167,744	178,393
Other non-current liabilities	13,330	6,621
Commitments and contingencies (Note 7)
Shareholders’ equity:
Ordinary shares	6	6
Non-voting euro deferred shares	55	55
Capital redemption reserve	471	471
Additional paid-in capital	1,184,965	1,151,010
Accumulated other comprehensive income	19,220	31,046
Accumulated deficit	(29,264)	(61,296)
Total shareholders’ equity	1,175,453	1,121,292
Total liabilities and shareholders’ equity	$ 2,093,880	$ 1,966,493

Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues:
Product sales, net	$ 206,564	$ 123,002	$ 401,216	$ 224,454
Royalties and contract revenues	1,688	1,229	3,273	2,307
Total revenues	208,252	124,231	404,489	226,761
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	25,031	12,289	52,251	20,033
Selling, general and administrative	77,506	57,224	148,034	101,580
Research and development	9,250	2,321	19,997	6,280
Intangible asset amortization	19,399	12,970	38,954	23,702
Total operating expenses	131,186	84,804	259,236	151,595
Income from operations	77,066	39,427	145,253	75,166
Interest expense, net	(7,142)	(1,481)	(14,541)	(1,450)
Foreign currency loss	(385)	(240)	(114)	(258)
Loss on extinguishment and modification of debt	(3,749)	0	(3,749)	0
Income from continuing operations before income tax provision	65,790	37,706	126,849	73,458
Income tax provision	23,605	6,593	41,239	12,110
Income from continuing operations	42,185	31,113	85,610	61,348
Loss from discontinued operations	0	(3,968)	0	(6,522)
Net income	$ 42,185	$ 27,145	$ 85,610	$ 54,826
Basic income (loss) per ordinary share:
Income from continuing operations (in dollars per share)	$ 0.72	$ 0.55	$ 1.46	$ 1.11
Loss from discontinued operations (in dollars per share)	0.00	(0.07)	0.00	(0.12)
Net income (in dollars per share)	0.72	0.48	1.46	0.99
Diluted income (loss) per ordinary share:
Income from continuing operations (in dollars per share)	0.69	0.51	1.39	1.03
Loss from discontinued operations (in dollars per share)	0.00	(0.06)	0.00	(0.11)
Net income (in dollars per share)	$ 0.69	$ 0.45	$ 1.39	$ 0.92
Weighted-average ordinary shares used in per share computations:
Basic (in shares)	58,737	56,952	58,548	55,437
Diluted (in shares)	61,568	60,554	61,541	59,319

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Net income	$ 42,185	$ 27,145	$ 85,610	$ 54,826
Other comprehensive income (loss):
Foreign currency translation adjustments	8,614	(388)	(11,826)	(388)
Available-for-sale securities:
Net unrealized gain on available-for-sale securities, net of income taxes	0	(20)	0	8
Reclassification adjustments for gains included in earnings, net of income taxes	0	17	0	23
Other comprehensive income (loss)	8,614	(391)	(11,826)	(357)
Total comprehensive income	50,799	26,754	73,784	54,469
Segment, Continuing Operations [Member]
Available-for-sale securities:
Total comprehensive income	50,799	30,722	73,784	60,991
Segment, Discontinued Operations [Member]
Available-for-sale securities:
Total comprehensive income	$ 0	$ (3,968)	$ 0	$ (6,522)

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Operating activities
Net income	$ 85,610	$ 54,826
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of intangible assets	38,954	29,264
Depreciation	1,170	415
Loss on disposal of property and equipment	40	139
Share-based compensation	20,263	8,539
Excess tax benefit from share-based compensation	0	(6,238)
Acquisition accounting inventory fair value step-up	2,631	6,380
Change in fair value of contingent consideration	7,900	200
Deferred income taxes	(9,064)	0
Provision for losses on accounts receivable and inventory	1,236	17
Loss on extinguishment and modification of debt	3,749	0
Other non-cash transactions	3,251	309
Changes in assets and liabilities:
Accounts receivable	(39,015)	(7,427)
Inventories	(6,104)	789
Prepaid expenses and other current assets	(14,672)	(5,390)
Other long-term assets	(2,617)	(354)
Accounts payable	4,707	11,363
Accrued liabilities	(7,749)	10,771
Income taxes payable	(21,898)	5,568
Deferred revenue	(492)	250
Other non-current liabilities	6,709	(837)
Liability under government settlement	0	(7,320)
Net cash provided by operating activities	74,609	101,264
Investing activities
Acquisitions, net of cash acquired	0	(542,531)
Purchases of marketable securities	0	(37,443)
Proceeds from sale of marketable securities	0	81,246
Proceeds from maturities of marketable securities	0	31,988
Acquisition of intangible assets	(1,300)	0
Purchases of property and equipment	(4,710)	(2,494)
Purchase of product rights	0	(9,500)
Net cash used in investing activities	(6,010)	(478,734)
Financing activities
Net proceeds from issuance of debt	553,425	450,916
Proceeds from employee equity incentive and purchase plans and exercise of warrants	15,463	18,573
Share repurchases	(53,578)	0
Payment of employee withholding taxes related to share-based awards	(1,597)	(25,299)
Excess tax benefit from share-based compensation	0	6,238
Repayment of long-term debt	(463,124)	0
Net cash provided by financing activities	50,589	450,428
Effect of exchange rates on cash and cash equivalents	(2,077)	(491)
Net increase in cash and cash equivalents	117,111	72,467
Cash and cash equivalents, at beginning of period	387,196	82,076
Cash and cash equivalents, at end of period	$ 504,307	$ 154,543

The Company and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

The Company and Summary of Significant Accounting Policies

Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland, is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing innovative products that address unmet medical needs. Our strategy is to continue to create shareholder value by:


•	Growing sales of the existing products in our portfolio, including by identifying new growth opportunities;


•	Acquiring additional marketed specialty products or products close to regulatory approval to leverage our existing expertise and infrastructure; and


•	Pursuing targeted development of a pipeline of post-discovery specialty product candidates.

On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma Public Limited Company, or Azur Pharma, were combined in a merger transaction, or the Azur Merger, accounted for as a reverse acquisition under the acquisition method of accounting for business combinations, with Jazz Pharmaceuticals, Inc. treated as the acquiring company for accounting purposes. As part of the Azur Merger, a wholly-owned subsidiary of Azur Pharma merged with and into Jazz Pharmaceuticals, Inc., with Jazz Pharmaceuticals, Inc. surviving the Azur Merger as a wholly-owned subsidiary of Jazz Pharmaceuticals plc. Prior to the Azur Merger, Azur Pharma changed its name to Jazz Pharmaceuticals plc.

On June 12, 2012, we completed the acquisition of EUSA Pharma Inc., or EUSA Pharma, which we refer to as the EUSA Acquisition.

Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries, including its predecessor Jazz Pharmaceuticals, Inc. All references to “Azur Pharma” are references to Jazz Pharmaceuticals plc (f/k/a Azur Pharma Public Limited Company) and its consolidated subsidiaries prior to the effective time of the Azur Merger on January 18, 2012. All references to “EUSA Pharma” are references to EUSA Pharma Inc. and its consolidated subsidiaries prior to the effective time of the EUSA Acquisition on June 12, 2012.

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission, or SEC, for interim reporting. As permitted under those rules, certain footnotes and other financial information that are normally required by U.S. generally accepted accounting principles, or GAAP, can be condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the annual consolidated financial statements and accompanying notes of Jazz Pharmaceuticals plc included in its Annual Report on Form 10-K for the year ended December 31, 2012. The results of operations of the acquired Azur Pharma and EUSA Pharma businesses, along with the estimated fair values of the assets acquired and liabilities assumed in each transaction, have been included in our condensed consolidated financial statements since the effective dates of the Azur Merger and the EUSA Acquisition, respectively.

In the opinion of management, these condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of our financial position and operating results. The results for the three and six months ended June 30, 2013 are not necessarily indicative of the results to be expected for the year ending December 31, 2013, for any other interim period or for any future period.

Certain prior period amounts presented in the accompanying footnotes have been reclassified to conform to current period presentation, as described in Note 2.

These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our wholly-owned subsidiaries and intercompany transactions and balances have been eliminated.

Significant Risks and Uncertainties

Our financial results are significantly influenced by sales of Xyrem^® (sodium oxybate) oral solution. Maintaining or increasing sales of Xyrem in its approved indications is subject to a number of risks and uncertainties, including the potential introduction of generic competition, changed or increased regulatory restrictions, and continued acceptance of Xyrem as safe and effective by physicians and patients. Two abbreviated new drug applications, or ANDAs, have been filed with the United States Food and Drug Administration, or FDA, by third parties seeking to market generic versions of Xyrem. We have sued both third parties for infringement of our patents, and the litigation proceedings are ongoing. We cannot predict the timing or outcome of these proceedings. We expect that the approval of an ANDA that results in the launch of a generic version of Xyrem would have a material adverse effect on our business, financial condition, results of operations and growth prospects. In addition, we are continuing our work on various regulatory matters, including our work with the FDA on updated documents that we have submitted to the FDA on our risk management and controlled distribution system for Xyrem, which we refer to as the Xyrem Risk Management Program. The updated documents are intended to conform to current formatting requirements for risk evaluation and mitigation strategies, or REMS, required by law, as well as to make other updates to the program and its documentation. While we cannot predict the timing of finalization, or the final terms, of approved REMS documents for Xyrem, we expect that the FDA will require final REMS documents that will result in, or permit, modifications to aspects of the Xyrem Risk Management Program, which may include the ability to distribute Xyrem through more than one pharmacy. We also expect that the final REMS documents will include requirements that are not currently implemented in the Xyrem Risk Management Program. Any such modifications or additional requirements could potentially make it more difficult or expensive for us to distribute Xyrem, make it easier for future generic competitors to enter the market and/or negatively affect sales of Xyrem.

In addition to risks related specifically to Xyrem, we are subject to risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including: the challenges of protecting our intellectual property rights; delays or problems in the supply or manufacture of our products, particularly because we maintain limited inventories of certain products, including products for which our supply demands are growing, and we are dependent on single source suppliers to continue to meet our ongoing commercial needs; the need to obtain appropriate pricing and reimbursement for our products in an increasingly challenging environment due to, among other things, the attention being paid to health care cost containment and other austerity measures in the United States and worldwide; the ongoing regulation and oversight by the FDA, the U.S. Drug Enforcement Administration, or DEA, and non-U.S. regulatory agencies, including with respect to product labeling, requirements for distribution, obtaining sufficient DEA quotas where needed, marketing and promotional activities, adverse event reporting and product recalls or withdrawals; the challenges of achieving and maintaining commercial success of our products, such as obtaining sustained acceptance of our products by patients, physicians and payors; and the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval. Other risks and uncertainties related to our ability to execute on our strategy include our ability to identify and acquire, in-license or develop additional products or product candidates to grow our business; and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt obligations.

Concentrations of Risk

Financial instruments that potentially subject us to concentrations of credit risk consist of cash equivalents and marketable securities. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.

We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to hospitals, pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of June 30, 2013, five customers accounted for 87% of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliate CuraScript, Inc., or Express Scripts, which accounted for 70% of gross accounts receivable, and Accredo Health Group, Inc., or Accredo, which accounted for 10% of gross accounts receivable. As of December 31, 2012, five customers accounted for 78% of gross accounts receivable, including Express Scripts, which accounted for 51% of gross accounts receivable, and Accredo, which accounted for 11% of gross accounts receivable.

We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

Net Income per Ordinary Share

Basic net income per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net income per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary shares outstanding. Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):



	Three Months Ended June 30,					Six Months Ended June 30,
	2013		2012			2013		2012
Numerator:
Income from continuing operations	$	42,185	$	31,113		$	85,610	$	61,348
Loss from discontinued operations	—		(3,968		)	—		(6,522		)
Net income	$	42,185	$	27,145		$	85,610	$	54,826
Denominator:
Weighted-average ordinary shares - basic	58,737		56,952			58,548		55,437
Dilutive effect of employee equity incentive and purchase plans	1,414		1,440			1,456		1,633
Dilutive effect of warrants	1,417		2,162			1,537		2,249
Weighted-average ordinary shares - diluted	61,568		60,554			61,541		59,319

Basic income (loss) per ordinary share:
Income from continuing operations	$	0.72	$	0.55		$	1.46	$	1.11
Loss from discontinued operations	—		(0.07		)	—		(0.12		)
Net income	$	0.72	$	0.48		$	1.46	$	0.99
Diluted income (loss) per ordinary share:
Income from continuing operations	$	0.69	$	0.51		$	1.39	$	1.03
Loss from discontinued operations	—		(0.06		)	—		(0.11		)
Net income	$	0.69	$	0.45		$	1.39	$	0.92

Potentially dilutive ordinary shares from employee equity plans and warrants are determined by applying the treasury stock method to the assumed exercise of warrants and share options, the assumed vesting of outstanding restricted stock units, or RSUs, and the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP. The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):



	Three Months Ended June 30,		Six Months Ended June 30,
	2013	2012	2013	2012
Options to purchase ordinary shares and RSUs	2,839	1,522	2,596	1,079

Recent Accounting Pronouncements

In July 2013, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, or ASU No. 2013-11, which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. ASU No. 2013-11 will be effective for us beginning January 1, 2014. We do not anticipate that the adoption of this standard will have a material impact on our financial position.

In March 2013, the FASB issued ASU No. 2013-05, “Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”, or ASU No. 2013-05. The objective of ASU No. 2013-05 is to resolve the diversity in practice regarding the release into net income of the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. ASU No. 2013-05 will be effective for us beginning January 1, 2014. We do not anticipate that the adoption of this standard will have a material impact on our results of operations or financial position, absent any material transactions involving the derecognition of subsidiaries or groups of assets within a foreign entity.

Inventories

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following (in thousands):



	June 30, 2013		December 31, 2012
Raw materials	$	6,090	$	4,979
Work in process	7,194		5,410
Finished goods	14,846		16,136
Total inventories	$	28,130	$	26,525

Certain inventories have been reclassified in the comparative period in order to conform to current period presentation. Inventories of $4.2 million previously classified as raw materials have been reclassified to work in process. As of June 30, 2013 and December 31, 2012, the fair value of inventories acquired included a step-up in the value of inventories of $1.3 million and $4.0 million, respectively.

Fair Value Measurement

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value Measurement

Cash and cash equivalents consisted of the following (in thousands):



	June 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	350,469	$	—	$	—	$	350,469	$	350,469	$	—
Time deposits	151,070		—		—		151,070		151,070		—
Money market funds	2,768		—		—		2,768		2,768		—
Totals	$	504,307	$	—	$	—	$	504,307	$	504,307	$	—


	December 31, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	343,548	$	—	$	—	$	343,548	$	343,548	$	—
Money market funds	43,648		—		—		43,648		43,648		—
Totals	$	387,196	$	—	$	—	$	387,196	$	387,196	$	—

Cash equivalents are considered available-for-sale. We use the specific-identification method for calculating realized gains and losses on securities sold and include them in interest expense, net in the condensed consolidated statements of income. All available-for-sale securities held as of June 30, 2013 and December 31, 2012 were cash equivalents.

The following table summarizes, by major security type, our available-for-sale securities and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):



	June 30, 2013								December 31, 2012
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Estimated Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Unobservable Inputs (Level 3)		Total Estimated Fair Value
Assets:
Available-for-sale securities
Time deposits	$	—	$	151,070	$	—	$	151,070	$	—	$	—	$	—
Money market funds	2,768		—		—		2,768		43,648		—		43,648
Totals	$	2,768	$	151,070	$	—	$	153,838	$	43,648	$	—	$	43,648
Liabilities:
Contingent consideration	$	—	$	—	$	42,700	$	42,700	$	—	$	34,800	$	34,800

As of June 30, 2013, our available-for-sale securities included time deposits and money market funds and their carrying values were approximately equal to their fair values. As of December 31, 2012, our available-for-sale securities included money market funds. There were no transfers between the different levels of the fair value hierarchy in 2013 or in 2012.

As part of the EUSA Acquisition, we agreed to make an additional contingent payment of $50.0 million in cash if Erwinaze^® (asparaginase Erwinia chrysanthemi) achieves U.S. net sales of $124.5 million or greater in 2013. The fair value measurement of this contingent consideration obligation is determined using unobservable Level 3 inputs. These inputs include the probability of 2013 U.S. net sales of Erwinaze equaling or exceeding the $124.5 million threshold and the discount rate. A significant increase or decrease in the estimated probability of meeting the milestone threshold would result in a significantly higher or lower fair value measurement, respectively. The range of the estimated contingent payment is from zero if 2013 U.S. net sales of Erwinaze are less than $124.5 million to $50.0 million if 2013 U.S. net sales of Erwinaze equal or exceed $124.5 million.

The change in fair value of the contingent consideration payable was estimated as follows (in thousands):



	Level 3
Balance at December 31, 2012	$	34,800
Fair value adjustment recorded within selling, general and administrative expenses	7,900
Balance at June 30, 2013	$	42,700

In 2013, the fair value adjustment reflects a change in the estimated probability of meeting the milestone threshold and the impact of discounting as a result of the passage of time.

As of June 30, 2013, the estimated fair value of our $557.2 million principal amount of our new term loans was $557.9 million and the carrying amount was $552.3 million. The fair value was determined using quotes from the administrative agent of our credit facility that are based on the bid/ask prices of our new term loans (Level 2). For additional information related to our new term loans, see Note 6.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Certain Balance Sheet Items

6 Months Ended

Jun. 30, 2013

Certain Balance Sheet Items [Abstract]

Certain Balance Sheet Items

Property and equipment consisted of the following (in thousands):



	June 30, 2013			December 31, 2012
Computer software	$	5,371		$	4,292
Construction-in-progress	4,204			1,135
Computer equipment	4,116			3,687
Leasehold improvements	3,980			3,899
Furniture and fixtures	1,934			1,953
Machinery and equipment	78			94
Subtotal	19,683			15,060
Less accumulated depreciation and amortization	(8,915		)	(7,779		)
Property and equipment, net	$	10,768		$	7,281

Accrued liabilities consisted of the following (in thousands):



	June 30, 2013		December 31, 2012
Rebates and other sales deductions	$	31,799	$	29,235
Sales returns reserve	24,039		26,385
Employee compensation and benefits	17,739		24,900
Royalties	3,898		3,271
Professional fees	1,660		2,163
Other	17,636		18,712
Total accrued liabilities	$	96,771	$	104,666

Goodwill and Intangible Assets

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

The gross carrying amount of goodwill was as follows (in thousands):



Balance at December 31, 2012	$	442,600
Foreign exchange	(3,586		)
Balance at June 30, 2013	$	439,014

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):



	June 30, 2013								December 31, 2012
	Remaining Weighted- Average Useful Life (In years)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Acquired developed technologies	11.9	$	924,153	$	(135,696	)	$	788,457	$	930,834	$	(97,578	)	$	833,256
Trademarks	1.5	2,600		(2,190		)	410		2,600		(2,054		)	546
Total finite-lived intangible assets		926,753		(137,886		)	788,867		933,434		(99,632		)	833,802
Acquired IPR&D assets		34,109		—			34,109		36,150		—			36,150
Total intangible assets		$	960,862	$	(137,886	)	$	822,976	$	969,584	$	(99,632	)	$	869,952

Based on finite-lived intangible assets recorded as of June 30, 2013, and assuming the underlying assets will not be impaired in the future and that we will not change the expected lives of the assets, future amortization costs were estimated as follows (in thousands):



Year Ending December 31,	Estimated Amortization Expense
2013 (remainder)	$	38,828
2014	77,459
2015	71,419
2016	67,090
2017	66,998
Thereafter	467,073
Total	$	788,867

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-Term Debt

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Long-term Debt

Long-Term Debt

Amendment of Credit Facility and Term Loan Refinancing

On June 13, 2013, Jazz Pharmaceuticals plc, as guarantor, and certain of its wholly-owned subsidiaries, as borrowers, entered into an amendment of our original credit agreement, dated as of June 12, 2012, with Barclays Bank PLC, as administrative agent, and certain other lenders.

The amended credit agreement provides for $557.2 million principal amount of new term loans and a new revolving credit facility of $200.0 million that replaces the revolving credit facility of $100.0 million provided for under the original credit agreement. We used a portion of the proceeds from the new term loans to refinance in full the outstanding term loans under the original credit agreement in an aggregate principal amount of $457.2 million, or the original term loans. The new term loans have the same June 12, 2018 maturity date that was applicable to the original term loans. Future loans under the new revolving credit facility, if any, will have the same June 12, 2017 maturity date that was applicable under the original credit agreement.

The new term loans bear interest, at our option, at a rate equal to either the LIBOR rate, plus an applicable margin of 2.75% per annum (subject to a 0.75% LIBOR floor), or the prime lending rate, plus an applicable margin equal to 1.75% per annum (subject to a 1.75% prime rate floor). Borrowings under the new revolving credit facility bear interest, at our option, at a rate equal to either the LIBOR rate, plus an applicable margin of 2.50% per annum, or the prime lending rate, plus an applicable margin equal to 1.50% per annum, subject to reduction by 0.25% or 0.50% based upon our secured leverage ratio. The new revolving credit facility has a commitment fee payable on the undrawn amount ranging from 0.25% to 0.50% per annum based upon our secured leverage ratio.

The borrowers’ obligations under the amended credit agreement and any hedging or cash management obligations entered into with a lender or an affiliate of a lender are guaranteed by Jazz Pharmaceuticals plc and certain of its subsidiaries, referred to below as restricted subsidiaries, and are secured by substantially all of their assets.

We may make voluntary prepayments of principal at any time without payment of a premium, except that a 1% premium would apply to any repricing of the new term loans effected on or prior to December 13, 2013. We are required to make mandatory prepayments of the new term loans (without payment of a premium) with (1) net cash proceeds from certain non-ordinary course asset sales (subject to reinvestment rights and other exceptions), (2) net cash proceeds from issuances of debt (other than certain permitted debt), (3) beginning with the fiscal year ending December 31, 2014, 50% of our excess cash flow as defined in the amended credit agreement (subject to decrease to 25% if our secured leverage ratio is equal to or less than 2.25 to 1.00 and greater than 1.25 to 1.00 or 0% if our secured leverage ratio is equal to or less than 1.25 to 1.00), and (4) casualty proceeds and condemnation awards (subject to reinvestment rights and other exceptions).

Principal repayments of the new term loans are due quarterly beginning in September 2013 and are equal to 1.0% of the original principal amount with any remaining balance payable on the final maturity date. Scheduled maturities with respect to the new term loans are as follows (in thousands):



Year Ending December 31,	Scheduled New Term Loan Maturities
2013 (remainder)	$	2,786
2014	5,572
2015	5,572
2016	5,572
2017	5,572
Thereafter	532,114
Total	$	557,188

The amended credit agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to Jazz Pharmaceuticals plc and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. The amended credit agreement contains a financial covenant that requires Jazz Pharmaceuticals plc and its restricted subsidiaries to maintain a maximum secured leverage ratio. We are currently in compliance with our financial covenants.

The refinancing of the original term loans involved multiple lenders who were considered members of a loan syndicate. In determining whether the refinancing was to be accounted for as a debt extinguishment or modification, we considered whether the creditors remained the same or changed and whether the change in debt terms was substantial. The debt terms were considered substantially different if the present value of the cash flows of the new term loans was at least 10% different from the present value of the remaining cash flows of the original term loans, or the 10% Test. We performed a separate 10% Test for each individual creditor participating in the loan syndication. The loans of creditors who did not participate in the amended credit agreement were accounted for as a debt extinguishment. When there was a change in principal balance for individual creditors, in applying the 10% Test, we used the cash flows related to the lowest common principal balance, or the Net Method. Under the Net Method, any principal in excess of a creditor’s reinvested principal balance was treated as a new, separate debt issuance, and any decrease in principal was treated as a partial extinguishment of debt.

For debt considered to be extinguished, the unamortized deferred financing costs and unamortized original issue discount associated with the extinguished debt were expensed. For debt considered to be modified, the unamortized deferred financing costs and unamortized original issue discount associated with the modified debt continue to be amortized, new creditor fees were capitalized and new third party fees were expensed. For new creditors, new creditor fees and new third party fees were capitalized. Deferred financing costs of $11.7 million and an original issue discount of $4.9 million were associated with modified and new debt and will be amortized to interest expense using the interest method over the life of the new term loans.

As the borrowing capacity relating to each creditor under the new revolving credit facility was greater than that under the original revolving credit facility, unamortized deferred financing costs, new creditor fees and new third party fees, totaling $4.7 million, were associated with the new arrangement and were deferred and are being amortized to interest expense on a straight-line basis over the life of the facility. We did not borrow under the original revolving credit facility and, as of June 30, 2013, we had not borrowed under the new revolving credit facility.

The refinancing resulted in a $3.7 million charge in the three and six months ended June 30, 2013, which was comprised of $2.7 million related to the expensing of unamortized deferred financing costs and unamortized original issue discount associated with extinguished debt and $1.0 million related to new third party fees associated with modified debt.

As of June 30, 2013, the interest rate on the new term loans was 3.5%. Interest expense associated with the new term loans is recorded using the interest method and includes non-cash interest related to the amortization of the debt discount and debt issuance costs. As of June 30, 2013, the effective interest rate on the new term loans was 4.3%. As of June 30, 2013, the current portion of the carrying amount of the new term loans was $5.6 million and the non-current portion was $546.7 million.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Indemnification

In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us. To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.

We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however, we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming the applicability of coverage and the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities relating to these obligations as of June 30, 2013 and December 31, 2012. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.

Lease and Other Commitments

We have noncancelable operating leases for our office buildings and we are obligated to make payments under noncancelable operating leases for automobiles used by our sales force. Future minimum lease payments under our noncancelable operating leases at June 30, 2013 were as follows (in thousands):



Year Ending December 31,	Lease Payments
2013 (remainder)	$	4,300
2014	8,714
2015	7,988
2016	4,942
2017	2,599
Thereafter	157
Total	$	28,700

In April 2013, we entered into a new operating lease agreement for additional office space in Palo Alto for a term of three years with an option to extend for one additional year.

As of June 30, 2013, we had $34.5 million of noncancelable purchase commitments due within one year, primarily related to agreements with third party manufacturers.

Legal Proceedings

We are involved in several legal proceedings, including the following matters:

Xyrem ANDA Matters: On October 18, 2010, we received a Paragraph IV Patent Certification notice, or Paragraph IV Certification, from Roxane Laboratories, Inc., or Roxane, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. Roxane’s Paragraph IV Certification alleged that all five patents then listed for Xyrem in the FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” or Orange Book, on the date of the Paragraph IV Certification are invalid, unenforceable or not infringed by Roxane’s proposed generic product. On November 22, 2010, we filed a lawsuit against Roxane in response to Roxane’s Paragraph IV Certification in the United States District Court for the District of New Jersey, or the District Court. We are seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe our patents. Two additional method of use patents covering the distribution system for Xyrem were issued in December 2010 and February 2011, respectively, and were listed in the Orange Book, and we filed lawsuits against Roxane in February 2011 and again in May 2011 to include these additional patents in the litigation in response to Roxane’s Paragraph IV Certifications against each of these patents, and also to include another issued patent in the litigation which is not listed in the Orange Book. These additional lawsuits were subsequently consolidated with the action filed on November 22, 2010. On April 26, 2012, the District Court held a Markman hearing, a pretrial hearing following which the trial judge construes the claims of the patents at issue in a lawsuit, and the District Court issued a Markman order construing the claims of the patents then involved in the litigation in September 2012. Two new patents, one covering a formulation of Xyrem and the other covering use of Xyrem for treatment of narcolepsy (Patent Nos. 8,263,650 and 8,324,275), or the ’650 patent and the ’275 patent, were issued in September 2012 and December 2012, respectively, and were listed in the Orange Book. In October 2012, we filed a new lawsuit in the District Court against Roxane in response to Roxane’s Paragraph IV Certification against the ’650 patent, or the ’650 case, and in December 2012, we filed a lawsuit in the District Court against Roxane alleging infringement of the ’275 patent, or the ’275 case. In April 2013, the District Court issued an order consolidating the three lawsuits and an order scheduling discovery and other deadlines for the consolidated case. Under the scheduling order, fact discovery concerning the ’650 and ’275 patents will remain open until September 2013, with Markman briefing concerning the ’650 and ’275 patents scheduled to occur between July and October 2013. Expert discovery involving all ten of the patents involved in the consolidated case is scheduled to begin following the issuance of any Markman order, and is expected to last approximately five and a half months. Although no trial date for the consolidated case has been scheduled, based on the scheduling order, we anticipate that trial in the consolidated case could occur as early as mid-2014. However, the actual timing of events in this litigation may be significantly earlier or later than contemplated by the scheduling order, and we cannot predict the timing or outcome of events in this litigation. In accordance with the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, as a result of our having filed a timely lawsuit against Roxane, FDA approval of Roxane’s ANDA had been stayed until April 18, 2013, which was 30 months after our October 18, 2010 receipt of Roxane’s Paragraph IV Certification, but that stay has expired.

On December 10, 2012, we received a Paragraph IV Certification from Amneal Pharmaceuticals, LLC, or Amneal, that it had submitted an ANDA to the FDA requesting approval to market a generic version of Xyrem. Amneal’s Paragraph IV Certification alleged that seven patents listed for Xyrem in the Orange Book are not infringed by Amneal’s proposed generic product. Amneal’s Paragraph IV Certification further alleged that an eighth patent listed in the Orange Book for Xyrem is invalid. On December 13, 2012, we received a supplemental Paragraph IV Certification alleging that a ninth patent listed in the Orange Book for Xyrem is invalid. On January 18, 2013, we filed a lawsuit against Amneal in response to Amneal’s Paragraph IV Certifications in the District Court. We are seeking a permanent injunction to prevent Amneal from introducing a generic version of Xyrem that would infringe our patents. In accordance with the Hatch-Waxman Act, as a result of having filed a timely lawsuit against Amneal, FDA approval of Amneal’s ANDA will be stayed until the earlier of (i) June 10, 2015, which is 30 months after our receipt of Amneal’s Paragraph IV Certification on December 10, 2012, or (ii) a District Court decision finding that the identified patents are invalid, unenforceable or not infringed. We cannot predict the outcome of this matter. On August 2, 2013, we received a supplemental Paragraph IV Certification alleging that a tenth patent listed in the Orange Book for Xyrem would not be infringed by Amneal’s proposed generic product.

On May 18, 2012, we submitted a Citizen Petition to the FDA that addressed the legal and scientific bases for requiring in vivo bioequivalence studies for generic formulations of Xyrem. Among other actions requested of the FDA, this petition requested that the FDA (i) not accept for review, review, or approve any ANDA referencing Xyrem unless and until the FDA has published bioequivalence requirements in the Orange Book specifying whether in vitro bioequivalence studies, in vivo bioequivalence studies, or both, are required for such ANDAs and (ii) require in vivo bioequivalence studies for any sodium oxybate drug product for which approval is sought in an ANDA referencing Xyrem to the extent such drug product differs from Xyrem in manufacturing process, pH, excipients, impurities, degradants or contaminants. On November 13, 2012, the FDA denied this Citizen Petition. On July 10, 2012, we submitted a second Citizen Petition to the FDA that addressed the requirements for submission of any ANDA referencing Xyrem. This petition focused on our view that any ANDA referencing Xyrem must contain a proposed risk management system at the time it was or is filed in order to demonstrate, as required by law, that the new generic drug product would have the same labeling and conditions of use as Xyrem. Among other actions requested of the FDA, this petition asked the FDA to rescind the acceptance of any previously-accepted ANDA referencing Xyrem, including the Roxane ANDA, that did not contain a proposed risk management system at the time it was accepted for review. On December 13, 2012, the FDA denied this Citizen Petition. We are evaluating the FDA’s responses to both Citizen Petitions and potential further actions that we may take with respect to the issues raised in, and the FDA’s denials of, the Citizen Petitions. The FDA’s denial of the Citizen Petitions does not have a direct impact on the merits of our ongoing lawsuits with Roxane and Amneal. However, we cannot predict the effect of the denial of either of our Citizen Petitions, or the FDA’s stated positions in its responses to the Citizen Petitions, on the timing of the potential introduction of a generic version of Xyrem.

FazaClo ANDA Matters: Azur Pharma received Paragraph IV Certifications from three generics manufacturers, Barr Laboratories, Inc.; Novel Laboratories, Inc.; and Mylan Pharmaceuticals, Inc., indicating that ANDAs had been filed with the FDA requesting approval to market generic versions of FazaClo^® (clozapine, USP) LD orally disintegrating clozapine tablets. Azur Pharma and CIMA Labs Inc., or CIMA, a subsidiary of Teva Pharmaceutical Industries Limited, or Teva, our licensor and the entity whose drug-delivery technology is incorporated into FazaClo LD, filed a lawsuit in response to each certification claiming infringement based on such certification: against Barr Laboratories, Inc. on August 21, 2008, against Novel Laboratories, Inc. on November 25, 2008, and against Mylan Pharmaceuticals, Inc. on July 23, 2010. Each case was filed in the United States District Court for the District of Delaware. On July 6, 2011, CIMA, Azur Pharma and Teva, which had acquired Barr Laboratories, Inc., entered into an agreement settling the patent litigation and Azur Pharma granted a sublicense to an affiliate of Teva of Azur Pharma’s rights to have manufactured, market and sell a generic version of both FazaClo LD and FazaClo HD, as well as an option for supply of authorized generic product. The sublicense for FazaClo LD commenced in July 2012, and the sublicense for FazaClo HD will commence in May 2015, or earlier upon the occurrence of certain events. Teva exercised its option for supply of an authorized generic product for FazaClo LD and launched the authorized generic product at the end of August 2012. The Novel Laboratories, Inc. and Mylan Pharmaceuticals, Inc. matters have been stayed pending reexamination of the patents in the lawsuits. In May 2013, a decision was issued by the U.S. Patent and Trademark Office, or the USPTO, in one of the two reexamination proceedings, which held certain claims patentable. The other reexamination proceeding is still ongoing. We cannot predict the outcome of the matters with Novel Laboratories, Inc. and Mylan Pharmaceuticals, Inc., whether there will be an appeal of the May 2013 USPTO decision, the outcome of such an appeal in the first reexamination proceeding, the outcome of the other reexamination proceeding, or when the stays will be lifted.

Cutler Matter: On October 19, 2011, Dr. Neal Cutler, one of the original owners of FazaClo, filed a complaint against Azur Pharma and one of its subsidiaries, as well as Avanir Pharmaceuticals, Inc., or Avanir, in California Superior Court in the County of Los Angeles, or the Superior Court. The complaint alleges that Azur Pharma and its subsidiary breached certain contractual obligations. Azur Pharma acquired rights to FazaClo from Avanir in 2007. The complaint alleges that as part of the acquisition of FazaClo, Azur Pharma’s subsidiary agreed to assume certain contingent payment obligations to Dr. Cutler. The complaint further alleges that certain contingent payments are due because revenue thresholds have been achieved, entitling Dr. Cutler to either a $10.5 million or $25.0 million contingent payment, plus unspecified punitive damages and attorneys’ fees. On March 14, 2012, the Superior Court granted our petition to compel arbitration of the dispute in New York and stayed the Superior Court litigation. We submitted a complaint in arbitration alleging that Dr. Cutler’s suit had been improperly filed in Los Angeles and seeking a declaratory judgment that we have complied with all contractual obligations to Dr. Cutler. On July 25, 2012, the arbitrator dismissed the arbitration on the grounds that the parties’ dispute falls outside of the scope of the arbitration clause in the applicable contract. We have asked the Superior Court to vacate the arbitrator’s dismissal of the arbitration and appealed the Superior Court’s denial of our motion to the California Court of Appeal. In addition, on November 7, 2012, we filed challenges to the sufficiency of the complaint in the Superior Court, but the Superior Court case has been stayed pending the outcome of our appeal. This matter, like all litigation, carries certain risks, and there can be no assurance of the outcome.

From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.

Shareholders' Equity

6 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

Shareholders' Equity

Shareholders’ Equity

The following table presents a summary of ordinary shares issued or repurchased and related cash proceeds and payments (in thousands):



	Six months ended June 30, 2013					Six months ended June 30, 2012
	Shares		Cash			Shares	Cash
Proceeds from employee equity incentive and purchase plans and warrant exercises	1,080		$	15,463		2,678	$	18,573
Share repurchases	(846	)	(53,578		)	—	—
Employee withholding taxes related to share-based awards (1)	—		(1,597		)	—	(25,299		)
Azur Merger	—		—			12,360	—
Directors' deferred compensation plan	—		—			29	—
Totals	234		$	(39,712	)	15,067	$	(6,726	)

____________________

(1)

During the six months ended June 30, 2013, we paid $1.6 million of income tax withholdings on behalf of employees related to the net share settlement of vested RSUs. During the six months ended June 30, 2012, we paid $25.3 million of income tax withholdings on behalf of certain employees of Jazz Pharmaceuticals, Inc. related to the net share settlement of exercised share options in connection with the Azur Merger. The income tax withholdings paid were recorded as a reduction to additional paid-in capital.

Share Repurchase Program

In May 2013, our board of directors authorized a share repurchase program pursuant to which we may repurchase a number of ordinary shares having an aggregate repurchase price of up to $200 million, exclusive of any brokerage commissions. The authorization became effective immediately and has no set expiration date. Under this authorization, we may repurchase our ordinary shares through open market purchases, privately negotiated purchases or a combination of these transactions. The timing and amount of repurchases will depend on a variety of factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the amended credit agreement, corporate and regulatory requirements and market conditions. Share repurchases may be suspended or discontinued at any time without prior notice. We initiated purchases under this program in May 2013. In the three and six months ended June 30, 2013, we spent a total of $53.6 million to repurchase 0.8 million of our ordinary shares at an average total purchase price, including commissions, of $63.32 per share. All ordinary shares repurchased by the company were canceled. As of June 30, 2013, the remaining amount authorized for share repurchases was $146.4 million.

Accumulated Other Comprehensive Income

The components of accumulated other comprehensive income as of June 30, 2013 and December 31, 2012 were as follows (in thousands):



	Foreign Currency Translation Adjustments			Total Accumulated Other Comprehensive Income
Balance at December 31, 2012	$	31,046		$	31,046
Other comprehensive loss	(11,826		)	(11,826		)
Balance at June 30, 2013	$	19,220		$	19,220

During the six months ended June 30, 2013, other comprehensive loss reflects foreign currency translation adjustments which are primarily due to the strengthening of the U.S. dollar against the Euro.

Additional Paid in Capital

In April 2013, the Irish High Court approved a $1.6 billion reduction of the share premium account of Jazz Pharmaceuticals plc to offset its accumulated deficit, with the resulting reserve to be treated as distributable reserves of our parent company. This transaction impacted our parent company balance sheet only and had no impact on our U.S. GAAP consolidated balance sheet.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Share-Based Compensation

6 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands):



	Three Months Ended June 30,					Six Months Ended June 30,
	2013			2012		2013			2012
Selling, general and administrative	$	9,539		$	4,232	$	16,544		$	6,637
Research and development	1,479			522		2,522			1,037
Cost of product sales	488			294		1,197			655
Total share-based compensation expense, pre-tax	11,506			5,048		20,263			8,329
Tax benefit from share-based compensation expense	(3,535		)	—		(6,348		)	—
Total share-based compensation expense, net of tax	$	7,971		$	5,048	$	13,915		$	8,329

Share Options

The table below shows the number of shares underlying options granted to purchase our ordinary shares, the weighted-average assumptions used in the Black-Scholes option pricing model and the resulting weighted-average grant date fair value of share options granted:



	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Shares underlying options granted (in thousands)	161			96			1,172			921
Grant date fair value	$	27.53		$	27.64		$	27.72		$	27.87
Black-Scholes option pricing model assumption information:
Volatility	58		%	66		%	59		%	63		%
Expected term (years)	4.4			5.2			4.4			5.2
Range of risk-free rates	0.5-0.8%			0.7-1.1%			0.5-0.8%			0.7-1.1%
Expected dividend yield	—		%	—		%	—		%	—		%

Restricted Stock Units

The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
RSUs granted (in thousands)	75		48		522		453
Grant date fair value	$	59.43	$	49.55	$	59.00	$	51.59

The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares as of that date. The fair value of RSUs is recognized as expense ratably over the vesting period of four years.

As of June 30, 2013, compensation cost not yet recognized related to unvested share options and RSUs was $61.1 million and $47.6 million, respectively, which is expected to be recognized over a weighted-average period of 2.9 years and 3.2 years, respectively.

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2013
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In March 2013, we entered into an underwriting agreement with an underwriter and certain selling shareholders, pursuant to which the selling shareholders sold to the underwriter 5.4 million of our ordinary shares, resulting in aggregate gross proceeds to the selling shareholders of approximately $314.4 million, before deducting underwriting discounts, commissions and other offering expenses. The selling shareholders included entities affiliated with certain members of our board of directors and one of our directors. We did not receive any proceeds from the sale of our ordinary shares by the selling shareholders in the offering and, consistent with our obligations under existing registration rights agreements with those shareholders, we paid expenses of approximately $0.5 million in connection with the offering.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Segment and Other Information

6 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Segment and Other Information

Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker or, CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the development and commercialization of specialty pharmaceutical products. The following table presents a summary of total revenues (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Xyrem^® (sodium oxybate) oral solution	$	133,742	$	89,097	$	251,268	$	162,534
Erwinaze^® (asparaginase Erwinia chrysanthemi)/Erwinase^®	44,860		6,007		86,676		6,007
Prialt^® (ziconotide) intrathecal infusion	4,694		5,555		9,680		15,077
Psychiatry	11,764		19,789		29,414		37,487
Other	11,504		2,554		24,178		3,349
Product sales, net	206,564		123,002		401,216		224,454
Royalties and contract revenues	1,688		1,229		3,273		2,307
Total revenues	$	208,252	$	124,231	$	404,489	$	226,761

The following table presents a summary of total revenues attributed to geographic sources (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
United States	$	191,274	$	119,440	$	368,185	$	215,710
Europe	13,074		3,172		27,436		9,086
All other	3,904		1,619		8,868		1,965
Total revenues	$	208,252	$	124,231	$	404,489	$	226,761

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Express Scripts	64	%	69	%	62	%	68	%
Accredo	18	%	—	%	17	%	—	%

The following table presents total long-lived assets by location (in thousands):



	June 30, 2013		December 31, 2012
Ireland	$	3,528	$	2,437
United States	6,895		4,451
Other	345		393
Total long-lived assets (1)	$	10,768	$	7,281

_________________________


(1)	Long-lived assets consist of property and equipment.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Restructuring

6 Months Ended

Jun. 30, 2013

Restructuring and Related Activities [Abstract]

Restructuring

Termination Benefits

In June 2012, we initiated a restructuring plan to re-align certain support functions across the company following the Azur Merger and the EUSA Acquisition. In connection with this restructuring we incurred costs of severance for terminated employees as well as retention bonus costs for certain employees retained to assist with the transition process which was completed in June 2013. The one-time termination benefits were recorded over the remaining service period where employees were required to stay through their termination date to receive the benefits. We recorded costs related to these one-time termination benefits of $0.1 million and $1.0 million in the three and six months ended June 30, 2013, respectively, and $0.5 million in both the three and six months ended June 30, 2012, which are recorded within selling, general and administrative expenses in our condensed consolidated statements of income. To date, we have incurred one-time termination benefit costs under this plan of $3.8 million. We do not expect to incur any additional one-time termination benefit costs in connection with this plan.

Facility Closure Costs

In connection with our restructuring plan, we vacated our Langhorne, Pennsylvania facility in June 2013. We incurred facility closure costs of $0.4 million in both the three and six months ended June 30, 2013 for the remaining operating lease obligations related to this facility, net of estimated sublease rentals that could be reasonably obtained. Facility closure costs are recorded within selling, general and administrative expenses in our condensed consolidated statements of income. We do not expect to incur any additional facility closure costs in connection with this plan.

The following table summarizes the amounts related to restructuring for the six months ended June 30, 2013 (in thousands):



	Termination Benefits			Facility Closure Costs		Total
Balance at December 31, 2012	$	1,227		$	—	$	1,227
Costs incurred during the period	1,045			412		1,457
Cash payments	(1,404		)	—		(1,404		)
Balance at June 30, 2013	$	868		$	412	$	1,280

The balance at June 30, 2013 was included within accrued liabilities in our condensed consolidated balance sheet.

Discontinued Operations

6 Months Ended

Jun. 30, 2013

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

In 2012, we sold the women’s health business, a component of the acquired Azur Pharma business, to Meda Pharmaceuticals Inc. and Meda Pharma, Sàrl, or collectively, Meda. As part of the transaction, Meda purchased six women’s health products from us and offered positions to approximately 60 of our employees who directly supported the women’s health business.

Net revenue and loss from discontinued operations were as follows (in thousands):



	Three Months Ended June 30, 2012			Six Months Ended June 30, 2012
Product sales, net	$	5,308		$	11,192

Loss from discontinued operations (1)	$	(3,968	)	$	(6,522	)

____________________


(1)	There was no income tax on the loss from discontinued operations.

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2013
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our income tax provision was $23.6 million and $41.2 million for the three and six months ended June 30, 2013, respectively, compared to $6.6 million and $12.1 million for the same periods in 2012. Our effective tax rate from continuing operations was 35.9% and 32.5% for the three and six months ended June 30, 2013, respectively, compared to 17.5% and 16.5% for the same periods in 2012. The increase in the effective tax rate was primarily due to a higher level of profits subject to U.S. federal and state income taxes in 2013, the release of a valuation allowance against substantially all of our U.S federal and state deferred tax assets in the fourth quarter of 2012 and a provision for income taxes on operations we acquired as part of the EUSA Acquisition. The effective tax rates for the 2013 periods were higher than the Irish statutory rate of 12.5% primarily due to income taxable at a rate higher than the Irish statutory rate, certain uncertain tax positions, current year losses in some jurisdictions for which no tax benefit is available, and various expenses not deductible for tax purposes, partially offset by benefits from certain originating income tax credits. No provision for income tax in Ireland has been recognized on undistributed earnings of our foreign subsidiaries because we consider such earnings to be indefinitely reinvested. Our deferred tax assets are composed primarily of U.S. federal and state net operating loss carryforwards and tax credit carryforwards, foreign net operating loss carryforwards and other temporary differences. We maintain a valuation allowance against certain U.S. state and foreign deferred tax assets. Each reporting period, we evaluate the need for a valuation allowance on our deferred tax assets by jurisdiction. We are required to recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. As a result, we have established a liability for certain tax benefits which we judge may not be sustained upon examination. We file income tax returns in Ireland, in the U.S. (both at the federal level and in various state jurisdictions) and in certain other foreign jurisdictions, all of which typically have three to four tax years open at any point in time. Because of our net operating loss carryforwards and tax credit carryforwards, substantially all of our tax years remain open to federal, state, and foreign tax examination. Certain of our subsidiaries are currently under examination by the French tax authorities for fiscal years 2010, 2011 and 2012 and by the U.S. Internal Revenue Service for fiscal years 2010, 2011 and 2012 to the date of the Azur Merger. We do not anticipate that the amount of our existing liability for unrecognized tax benefits will significantly change within the next 12 months.

The Company and Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Basis of Presentation

Certain prior period amounts presented in the accompanying footnotes have been reclassified to conform to current period presentation, as described in Note 2.

These condensed consolidated financial statements include the accounts of Jazz Pharmaceuticals plc and our wholly-owned subsidiaries and intercompany transactions and balances have been eliminated.

Significant Risks and Uncertainties

Concentrations of Risk

We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.

Use of Estimates

Net Income per Ordinary Share



	Three Months Ended June 30,					Six Months Ended June 30,
	2013		2012			2013		2012
Numerator:
Income from continuing operations	$	42,185	$	31,113		$	85,610	$	61,348
Loss from discontinued operations	—		(3,968		)	—		(6,522		)
Net income	$	42,185	$	27,145		$	85,610	$	54,826
Denominator:
Weighted-average ordinary shares - basic	58,737		56,952			58,548		55,437
Dilutive effect of employee equity incentive and purchase plans	1,414		1,440			1,456		1,633
Dilutive effect of warrants	1,417		2,162			1,537		2,249
Weighted-average ordinary shares - diluted	61,568		60,554			61,541		59,319

Basic income (loss) per ordinary share:
Income from continuing operations	$	0.72	$	0.55		$	1.46	$	1.11
Loss from discontinued operations	—		(0.07		)	—		(0.12		)
Net income	$	0.72	$	0.48		$	1.46	$	0.99
Diluted income (loss) per ordinary share:
Income from continuing operations	$	0.69	$	0.51		$	1.39	$	1.03
Loss from discontinued operations	—		(0.06		)	—		(0.11		)
Net income	$	0.69	$	0.45		$	1.39	$	0.92



	Three Months Ended June 30,		Six Months Ended June 30,
	2013	2012	2013	2012
Options to purchase ordinary shares and RSUs	2,839	1,522	2,596	1,079

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References + Details

The Company and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Basic and Diluted Net Income per Ordinary Share Computation

Basic and diluted net income per ordinary share were computed as follows (in thousands, except per share amounts):



	Three Months Ended June 30,					Six Months Ended June 30,
	2013		2012			2013		2012
Numerator:
Income from continuing operations	$	42,185	$	31,113		$	85,610	$	61,348
Loss from discontinued operations	—		(3,968		)	—		(6,522		)
Net income	$	42,185	$	27,145		$	85,610	$	54,826
Denominator:
Weighted-average ordinary shares - basic	58,737		56,952			58,548		55,437
Dilutive effect of employee equity incentive and purchase plans	1,414		1,440			1,456		1,633
Dilutive effect of warrants	1,417		2,162			1,537		2,249
Weighted-average ordinary shares - diluted	61,568		60,554			61,541		59,319

Basic income (loss) per ordinary share:
Income from continuing operations	$	0.72	$	0.55		$	1.46	$	1.11
Loss from discontinued operations	—		(0.07		)	—		(0.12		)
Net income	$	0.72	$	0.48		$	1.46	$	0.99
Diluted income (loss) per ordinary share:
Income from continuing operations	$	0.69	$	0.51		$	1.39	$	1.03
Loss from discontinued operations	—		(0.06		)	—		(0.11		)
Net income	$	0.69	$	0.45		$	1.39	$	0.92

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share

The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income per ordinary share for the periods presented because including them would have an anti-dilutive effect (in thousands):



	Three Months Ended June 30,		Six Months Ended June 30,
	2013	2012	2013	2012
Options to purchase ordinary shares and RSUs	2,839	1,522	2,596	1,079

Inventories (Tables)

6 Months Ended

Jun. 30, 2013

Inventory Disclosure [Abstract]

Components of Inventories

Inventories consisted of the following (in thousands):



	June 30, 2013		December 31, 2012
Raw materials	$	6,090	$	4,979
Work in process	7,194		5,410
Finished goods	14,846		16,136
Total inventories	$	28,130	$	26,525

Fair Value Measurement (Tables)

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Cash Cash Equivalents and Marketable Securities

Cash and cash equivalents consisted of the following (in thousands):



	June 30, 2013
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	350,469	$	—	$	—	$	350,469	$	350,469	$	—
Time deposits	151,070		—		—		151,070		151,070		—
Money market funds	2,768		—		—		2,768		2,768		—
Totals	$	504,307	$	—	$	—	$	504,307	$	504,307	$	—


	December 31, 2012
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	343,548	$	—	$	—	$	343,548	$	343,548	$	—
Money market funds	43,648		—		—		43,648		43,648		—
Totals	$	387,196	$	—	$	—	$	387,196	$	387,196	$	—

Available-for-Sale Securities and Other Assets and Liabilities Measured at Fair Value on Recurring Basis



	June 30, 2013								December 31, 2012
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Estimated Fair Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Unobservable Inputs (Level 3)		Total Estimated Fair Value
Assets:
Available-for-sale securities
Time deposits	$	—	$	151,070	$	—	$	151,070	$	—	$	—	$	—
Money market funds	2,768		—		—		2,768		43,648		—		43,648
Totals	$	2,768	$	151,070	$	—	$	153,838	$	43,648	$	—	$	43,648
Liabilities:
Contingent consideration	$	—	$	—	$	42,700	$	42,700	$	—	$	34,800	$	34,800

Roll forward of contingent consideration

The change in fair value of the contingent consideration payable was estimated as follows (in thousands):



	Level 3
Balance at December 31, 2012	$	34,800
Fair value adjustment recorded within selling, general and administrative expenses	7,900
Balance at June 30, 2013	$	42,700

Certain Balance Sheet Items (Tables)

6 Months Ended

Jun. 30, 2013

Certain Balance Sheet Items [Abstract]

Property and Equipment

Property and equipment consisted of the following (in thousands):



	June 30, 2013			December 31, 2012
Computer software	$	5,371		$	4,292
Construction-in-progress	4,204			1,135
Computer equipment	4,116			3,687
Leasehold improvements	3,980			3,899
Furniture and fixtures	1,934			1,953
Machinery and equipment	78			94
Subtotal	19,683			15,060
Less accumulated depreciation and amortization	(8,915		)	(7,779		)
Property and equipment, net	$	10,768		$	7,281

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):



	June 30, 2013		December 31, 2012
Rebates and other sales deductions	$	31,799	$	29,235
Sales returns reserve	24,039		26,385
Employee compensation and benefits	17,739		24,900
Royalties	3,898		3,271
Professional fees	1,660		2,163
Other	17,636		18,712
Total accrued liabilities	$	96,771	$	104,666

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Gross Carrying Amount of Goodwill

The gross carrying amount of goodwill was as follows (in thousands):



Balance at December 31, 2012	$	442,600
Foreign exchange	(3,586		)
Balance at June 30, 2013	$	439,014

Gross Carrying Amounts and Net Book Values of Intangible Assets

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):



	June 30, 2013								December 31, 2012
	Remaining Weighted- Average Useful Life (In years)	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Acquired developed technologies	11.9	$	924,153	$	(135,696	)	$	788,457	$	930,834	$	(97,578	)	$	833,256
Trademarks	1.5	2,600		(2,190		)	410		2,600		(2,054		)	546
Total finite-lived intangible assets		926,753		(137,886		)	788,867		933,434		(99,632		)	833,802
Acquired IPR&D assets		34,109		—			34,109		36,150		—			36,150
Total intangible assets		$	960,862	$	(137,886	)	$	822,976	$	969,584	$	(99,632	)	$	869,952

Estimated Future Amortization Costs



Year Ending December 31,	Estimated Amortization Expense
2013 (remainder)	$	38,828
2014	77,459
2015	71,419
2016	67,090
2017	66,998
Thereafter	467,073
Total	$	788,867

Long-Term Debt (Tables)

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Schedule of Maturities of New Term Loans

Scheduled maturities with respect to the new term loans are as follows (in thousands):



Year Ending December 31,	Scheduled New Term Loan Maturities
2013 (remainder)	$	2,786
2014	5,572
2015	5,572
2016	5,572
2017	5,572
Thereafter	532,114
Total	$	557,188

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Future Minimum Lease Payments under Noncancelable Operating Leases

Future minimum lease payments under our noncancelable operating leases at June 30, 2013 were as follows (in thousands):



Year Ending December 31,	Lease Payments
2013 (remainder)	$	4,300
2014	8,714
2015	7,988
2016	4,942
2017	2,599
Thereafter	157
Total	$	28,700

Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

Ordinary Shares Issued and Proceeds Received

The following table presents a summary of ordinary shares issued or repurchased and related cash proceeds and payments (in thousands):



	Six months ended June 30, 2013					Six months ended June 30, 2012
	Shares		Cash			Shares	Cash
Proceeds from employee equity incentive and purchase plans and warrant exercises	1,080		$	15,463		2,678	$	18,573
Share repurchases	(846	)	(53,578		)	—	—
Employee withholding taxes related to share-based awards (1)	—		(1,597		)	—	(25,299		)
Azur Merger	—		—			12,360	—
Directors' deferred compensation plan	—		—			29	—
Totals	234		$	(39,712	)	15,067	$	(6,726	)

____________________

(1)

Component of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive income as of June 30, 2013 and December 31, 2012 were as follows (in thousands):



	Foreign Currency Translation Adjustments			Total Accumulated Other Comprehensive Income
Balance at December 31, 2012	$	31,046		$	31,046
Other comprehensive loss	(11,826		)	(11,826		)
Balance at June 30, 2013	$	19,220		$	19,220

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6403732&loc=d3e21300-112643

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28,29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5

+ Details

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation Expense

Share-based compensation expense related to share options, RSUs and grants under our ESPP was as follows (in thousands):



	Three Months Ended June 30,					Six Months Ended June 30,
	2013			2012		2013			2012
Selling, general and administrative	$	9,539		$	4,232	$	16,544		$	6,637
Research and development	1,479			522		2,522			1,037
Cost of product sales	488			294		1,197			655
Total share-based compensation expense, pre-tax	11,506			5,048		20,263			8,329
Tax benefit from share-based compensation expense	(3,535		)	—		(6,348		)	—
Total share-based compensation expense, net of tax	$	7,971		$	5,048	$	13,915		$	8,329

Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model which was Used to Estimate Grant Date Fair Value per Share



	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
Shares underlying options granted (in thousands)	161			96			1,172			921
Grant date fair value	$	27.53		$	27.64		$	27.72		$	27.87
Black-Scholes option pricing model assumption information:
Volatility	58		%	66		%	59		%	63		%
Expected term (years)	4.4			5.2			4.4			5.2
Range of risk-free rates	0.5-0.8%			0.7-1.1%			0.5-0.8%			0.7-1.1%
Expected dividend yield	—		%	—		%	—		%	—		%

Schedule of Restricted Stock Unit activity

The table below shows the number of RSUs granted covering an equal number of our ordinary shares and the weighted-average grant date fair value of RSUs granted:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
RSUs granted (in thousands)	75		48		522		453
Grant date fair value	$	59.43	$	49.55	$	59.00	$	51.59

Segment and Other Information (Tables)

6 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Summary of Total Revenues

The following table presents a summary of total revenues (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Xyrem^® (sodium oxybate) oral solution	$	133,742	$	89,097	$	251,268	$	162,534
Erwinaze^® (asparaginase Erwinia chrysanthemi)/Erwinase^®	44,860		6,007		86,676		6,007
Prialt^® (ziconotide) intrathecal infusion	4,694		5,555		9,680		15,077
Psychiatry	11,764		19,789		29,414		37,487
Other	11,504		2,554		24,178		3,349
Product sales, net	206,564		123,002		401,216		224,454
Royalties and contract revenues	1,688		1,229		3,273		2,307
Total revenues	$	208,252	$	124,231	$	404,489	$	226,761

Summary of Total Revenues Attributed to Geographic Sources

The following table presents a summary of total revenues attributed to geographic sources (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
United States	$	191,274	$	119,440	$	368,185	$	215,710
Europe	13,074		3,172		27,436		9,086
All other	3,904		1,619		8,868		1,965
Total revenues	$	208,252	$	124,231	$	404,489	$	226,761

Summary of Revenues from Customers Representing More Than 10% of Total Revenues

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
Express Scripts	64	%	69	%	62	%	68	%
Accredo	18	%	—	%	17	%	—	%

Total Long-Lived Assets by Location

The following table presents total long-lived assets by location (in thousands):



	June 30, 2013		December 31, 2012
Ireland	$	3,528	$	2,437
United States	6,895		4,451
Other	345		393
Total long-lived assets (1)	$	10,768	$	7,281

_________________________


(1)	Long-lived assets consist of property and equipment.

Restructuring (Tables)

6 Months Ended

Jun. 30, 2013

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs



	Termination Benefits			Facility Closure Costs		Total
Balance at December 31, 2012	$	1,227		$	—	$	1,227
Costs incurred during the period	1,045			412		1,457
Cash payments	(1,404		)	—		(1,404		)
Balance at June 30, 2013	$	868		$	412	$	1,280

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2013

Discontinued Operations and Disposal Groups [Abstract]

Schedule of disposal groups

Net revenue and loss from discontinued operations were as follows (in thousands):



	Three Months Ended June 30, 2012			Six Months Ended June 30, 2012
Product sales, net	$	5,308		$	11,192

Loss from discontinued operations (1)	$	(3,968	)	$	(6,522	)

____________________


(1)	There was no income tax on the loss from discontinued operations.

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References + Details

The Company and Summary of Significant Accounting Policies - Additional Information (Detail) - Customer	Jun. 30, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies [Line Items]
Number of customers with significant accounts receivable	5	5
Percentage of gross accounts receivable	87.00%	78.00%
Express Scripts [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable	70.00%	51.00%
Accredo Health Group, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of gross accounts receivable	10.00%	11.00%

Basic and Diluted Net Income (Loss) per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Numerator:
Income from continuing operations	$ 42,185	$ 31,113	$ 85,610	$ 61,348
Loss from discontinued operations	0	(3,968)	0	(6,522)	$ 0
Net income	$ 42,185	$ 27,145	$ 85,610	$ 54,826
Denominator:
Weighted-average ordinary shares - basic (in shares)	58,737	56,952	58,548	55,437
Dilutive effect of employee equity incentive and purchase plans (in shares)	1,414	1,440	1,456	1,633
Dilutive effect of warrants (in shares)	1,417	2,162	1,537	2,249
Weighted-average ordinary shares - diluted (in shares)	61,568	60,554	61,541	59,319
Basic income (loss) per ordinary share:
Income from continuing operations (in dollars per share)	$ 0.72	$ 0.55	$ 1.46	$ 1.11
Loss from discontinued operations (in dollars per share)	0.00	(0.07)	0.00	(0.12)
Net income (in dollars per share)	0.72	0.48	1.46	0.99
Diluted income (loss) per ordinary share:
Income from continuing operations (in dollars per share)	0.69	0.51	1.39	1.03
Loss from discontinued operations (in dollars per share)	0.00	(0.06)	0.00	(0.11)
Net income (in dollars per share)	$ 0.69	$ 0.45	$ 1.39	$ 0.92

Weighted-Average Ordinary Shares Excluded from Computation of Diluted Net Income per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Accounting Policies [Abstract]
Options to purchase ordinary shares and RSUs	2,839	1,522	2,596	1,079

Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Raw materials	$ 14,846	$ 16,136
Work in process	7,194	5,410
Finished goods	6,090	4,979
Total inventories	$ 28,130	$ 26,525

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Schedule of Inventory [Line Items]
Inventory reclassified from raw materials to work in process		$ 4,200
Fair Value Adjustment to Inventory [Member]
Schedule of Inventory [Line Items]
Inventory, Step-up value	$ 1,322	$ 4,017

Summary of Cash, Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2011
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	$ 504,307	$ 387,196
Estimated Fair Value	504,307	387,196
Cash and cash equivalents	504,307	387,196	$ 154,543	$ 82,076
Cash [Member]
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	350,469	343,548
Estimated Fair Value	350,469	343,548
Cash and cash equivalents	350,469	343,548
Money market funds [Member]
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	2,768	43,648
Estimated Fair Value	2,768	43,648
Cash and cash equivalents	2,768	$ 43,648
Time deposits [Member]
Cash, cash equivalents and marketable securities [Line Items]
Amortized Cost	151,070
Estimated Fair Value	151,070
Cash and cash equivalents	$ 151,070

Fair Value - Additional Information (Detail) - USD ($)	Jun. 30, 2013	Dec. 31, 2012
Fair Value Measurements [Line Items]
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	$ 0	$ 0
Contingent consideration, non current	0	$ 34,800,000
Term Loans [Member]
Fair Value Measurements [Line Items]
Principal amount of term loan	557,200,000.0
Fair value of term loan	557,900,000
Carrying value of term loan	552,300,000
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements [Line Items]
Target sales of Erwinaze in 2013	124,500,000
Cash Distribution [Member] \| Minimum [Member]
Fair Value Measurements [Line Items]
Contingent consideration, non current	0
Cash Distribution [Member] \| Maximum [Member]
Fair Value Measurements [Line Items]
Contingent consideration, non current	$ 50,000,000

Fair Value Measurement Available-For-Sale Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Amortized Cost	$ 504,307	$ 387,196
Available-for-sale securities measured at fair value on recurring basis	504,307	387,196
Money market funds [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Amortized Cost	2,768	43,648
Available-for-sale securities measured at fair value on recurring basis	2,768	43,648
Time deposits [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Amortized Cost	151,070
Available-for-sale securities measured at fair value on recurring basis	151,070
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Fair Value, Measurements, Recurring [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Amortized Cost	2,768	43,648
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] \| Fair Value, Measurements, Recurring [Member] \| Money market funds [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Amortized Cost	2,768	43,648
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member] \| Contingent Consideration [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Contingent consideration	42,700	34,800
Estimate of Fair Value, Fair Value Disclosure [Member] \| Fair Value, Measurements, Recurring [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Available-for-sale securities measured at fair value on recurring basis	153,838	43,648
Contingent consideration	42,700	34,800
Estimate of Fair Value, Fair Value Disclosure [Member] \| Fair Value, Measurements, Recurring [Member] \| Money market funds [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Available-for-sale securities measured at fair value on recurring basis	2,768	$ 43,648
Estimate of Fair Value, Fair Value Disclosure [Member] \| Fair Value, Measurements, Recurring [Member] \| Time deposits [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Available-for-sale securities measured at fair value on recurring basis	151,070
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Amortized Cost	151,070
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member] \| Time deposits [Member]
Schedule of Available-for-sale Securities and Liabilities that are Measured at Fair Value [Line Items]
Amortized Cost	$ 151,070

Fair Value Measurement Level 3 Input Roll Forward (Details) - Contingent Consideration [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2013 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 34,800
Fair value adjustment recorded within selling, general and administrative expenses	7,900
Ending Balance	$ 42,700

Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Certain Balance Sheet Items [Abstract]
Computer software	$ 5,371	$ 4,292
Construction-in-progress	4,204	1,135
Computer equipment	4,116	3,687
Leasehold improvements	3,980	3,899
Furniture and fixtures	1,934	1,953
Machinery and equipment	78	94
Subtotal	19,683	15,060
Less accumulated depreciation and amortization	(8,915)	(7,779)
Property and equipment, net	$ 10,768	$ 7,281

Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Certain Balance Sheet Items [Abstract]
Rebates and other sales deductions	$ 31,799	$ 29,235
Sales returns reserve	24,039	26,385
Employee compensation and benefits	17,739	24,900
Royalties	3,898	3,271
Professional fees	1,660	2,163
Other	17,636	18,712
Total accrued liabilities	$ 96,771	$ 104,666

Goodwill and Intangible Assets - Additional Information (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2013 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 442,600
Foreign exchange	(3,586)
Goodwill, end of period	$ 439,014

Gross Carrying Amounts and Net Book Values of Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 926,753	$ 933,434
Accumulated Amortization - Finite-Lived Intangible Assets	(137,886)	(99,632)
Net Book Value - Finite-Lived Intangible Assets	788,867	833,802
Gross Carrying Amount - Total Intangible Assets	960,862	969,584
Net Book Value - Total Intangible Assets	822,976	869,952
Acquired IPR&D assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
In-process research and development	$ 34,109	36,150
Acquired developed technologies [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	11 years 10 months 24 days
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 924,153	930,834
Accumulated Amortization - Finite-Lived Intangible Assets	(135,696)	(97,578)
Net Book Value - Finite-Lived Intangible Assets	$ 788,457	833,256
Trademarks [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Remaining Weighted- Average Useful Life (In years)	1 year 6 months
Gross Carrying Amount - Finite-Lived Intangible Assets	$ 2,600	2,600
Accumulated Amortization - Finite-Lived Intangible Assets	(2,190)	(2,054)
Net Book Value - Finite-Lived Intangible Assets	$ 410	$ 546

Estimated Future Amortization Costs (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Estimated Amortization Expense
2013 (remainder)	$ 38,828
2014	77,459
2015	71,419
2016	67,090
2017	66,998
Thereafter	467,073
Net Book Value - Finite-Lived Intangible Assets	$ 788,867	$ 833,802

Debt (Details) - USD ($)		6 Months Ended
Debt (Details) - USD ($)	Jun. 13, 2013	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Jun. 12, 2012
Debt Instrument [Line Items]
Current portion of long-term debt		$ 5,572,000		$ 29,688,000
Repayment of long-term debt		463,124,000	$ 0
Long-term debt, less current portion		546,724,000		$ 427,073,000
2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Current portion of long-term debt		5,600,000
Long-term debt, less current portion		$ 546,700,000
2013 Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Credit facility borrowing capacity	$ 200,000,000
2013 Credit Agreement [Member] \| Revolving Credit Facility [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.50%
2013 Credit Agreement [Member] \| Revolving Credit Facility [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
2012 Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Credit facility borrowing capacity					$ 100,000,000.0
Term Loan [Member] \| 2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Principal amount of term loan	$ 557,188,000
Repricing premium before 12/13/13	1.00%
Percentage of principal amount for repayment		1.00%
Term Loan [Member] \| 2013 Credit Agreement [Member] \| LIBOR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.75%
Term loan interest rate minimum percentage	0.75%
Term Loan [Member] \| 2013 Credit Agreement [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.75%
Term loan interest rate minimum percentage	1.75%
Term Loan [Member] \| 2012 Credit Agreement [Member]
Debt Instrument [Line Items]
Repayment of long-term debt	$ 457,200,000
Rate One [Member] \| 2013 Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Interest rate reduction basis points	0.25%
Commitment fee on credit facility, percentage	0.25%
Rate One [Member] \| Term Loan [Member] \| 2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Mandatory prepayments as percentage of excess cash flow beginning in 2014	50.00%
Rate Two [Member] \| 2013 Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Interest rate reduction basis points	0.50%
Commitment fee on credit facility, percentage	0.50%
Rate Two [Member] \| Term Loan [Member] \| 2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Mandatory prepayments as percentage of excess cash flow beginning in 2014	25.00%
Rate Option Three [Member] \| Term Loan [Member] \| 2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Mandatory prepayments as percentage of excess cash flow beginning in 2014	0.00%

Schedule of Maturities (Details) - Term Loan [Member] - 2013 Credit Agreement [Member] $ in Thousands	Jun. 30, 2013 USD ($)
Debt Instrument [Line Items]
2013 (remainder)	$ 2,786
2014	5,572
2015	5,572
2016	5,572
2017	5,572
Thereafter	532,114
Long-term Debt	$ 557,188

Long-Term Debt Extinguishment and Modification of Debt (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jun. 13, 2013	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Debt Instrument [Line Items]
Debt financing costs		$ 1,049,000		$ 1,049,000
Expense cost of unamortized deferred finance costs and unamortized issue discount associated with extinguished debt		2,700,000		2,700,000
Loss on extinguishment and modification of debt		3,749,000	$ 0	3,749,000	$ 0
Current portion of long-term debt		5,572,000		5,572,000		$ 29,688,000
Long-term debt, less current portion		546,724,000		546,724,000		$ 427,073,000
2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Current portion of long-term debt		5,600,000		5,600,000
Long-term debt, less current portion		$ 546,700,000		$ 546,700,000
Term Loan [Member]
Debt Instrument [Line Items]
Original issue discount	$ 4,934,000
Unamortized deferred financing costs and new lender fees	11,749,000
Term Loan [Member] \| 2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Term loan interest rate		3.50%		3.50%
Term loan effective interest rate		4.30%		4.30%
Term loan, frequency of periodic payment				Quarterly
Revolving Credit Facility [Member] \| 2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Unamortized deferred financing costs and new lender fees	$ 4,718,000

Future Minimum Lease Payments under Noncancelable Operating Leases (Detail) $ in Thousands	Jun. 30, 2013 USD ($)
Lease Payments
2013 (remainder)	$ 4,300
2014	8,714
2015	7,988
2016	4,942
2017	2,599
Thereafter	157
Total	$ 28,700

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended
	Apr. 30, 2013	Jun. 30, 2013	Oct. 19, 2011
Commitments and Contingencies Disclosure [Line Items]
Noncancelable purchase commitments, due within one year		$ 34,500,000
Pending Litigation [Member]
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Range of Possible Loss, Minimum			$ 10,500,000.0
Loss Contingency, Range of Possible Loss, Maximum			$ 25,000,000
Lease Agreements [Member] \| Palo Alto [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Lease, Renewed Term	3 years

Ordinary Shares Issued, Repurchased and Related Cash Proceeds and Payments (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

May 31, 2013

Jun. 30, 2013

Jun. 30, 2012

Stock Activity [Line Items]

Share repurchases

$ (53,578)

$ 0

Payment of employee withholding taxes related to share-based awards

$ (1,597)

$ (25,299)

Ordinary Shares [Member]

Stock Activity [Line Items]

Proceeds from employee equity incentive and purchase plans and warrant exercises, shares

1,080

2,678

Shares repurchased, shares

(846)

Merger with Azur Pharma, shares issued

12,360

Directors deferred compensation plan, shares issued

Totals, shares issued

234

15,067

Proceeds from employee equity incentive and purchase plans and warrant exercises

$ 15,463

$ 18,573

Share repurchases

$ (53,578)

(53,578)

Payment of employee withholding taxes related to share-based awards

^[1]

(1,597)

(25,299)

Totals, cash proceeds and payments

$ (39,712)

$ (6,726)

Total amount authorized for repurchase of shares under share repurchase program

$ 200,000

Purchase price of shares (in dollars per share)

$ 63.32

Remaining amount authorized for repurchase of shares

$ 146,439

[1]

Component of Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2012			$ 31,046
Other comprehensive income (loss)	$ 8,614	$ (391)	(11,826)	$ (357)
Balance at June 30, 2013	19,220		19,220
Foreign Currency Translation Adjustments [Member]
Increase (Decrease) in Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Balance at December 31, 2012			31,046
Other comprehensive income (loss)			(11,826)
Balance at June 30, 2013	$ 19,220		$ 19,220

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Shareholders' Equity Additional Paid In Capital (Details) $ in Billions	Apr. 30, 2013 USD ($)
Stockholders' Equity Note [Abstract]
Parents company shareholders equity	$ 1.6

Share-Based Compensation Expense (Detail) - Share Options And Restricted Stock Units [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 11,506	$ 5,048	$ 20,263	$ 8,329
Tax benefit from share-based compensation expense	(3,535)	0	(6,348)	0
Total share-based compensation expense, net of tax	7,971	5,048	13,915	8,329
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	9,539	4,232	16,544	6,637
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	1,479	522	2,522	1,037
Cost of product sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 488	$ 294	$ 1,197	$ 655

Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model Which Was Used to Estimate Grant Date Fair Value per Share (Detail) - Employee Stock Option [Member] - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Schedule of Weighted Average Assumptions for Fair Values of Stock Options[Line Items]
Shares underlying options granted (in shares)	161	96	1,172	921
Weighted-average grant date fair value (in dollars per share)	$ 27.53	$ 27.64	$ 27.72	$ 27.87
Weighted-average volatility	58.00%	66.00%	59.00%	63.00%
Weighted-average expected term (years)	4 years 4 months 24 days	5 years 2 months 12 days	4 years 4 months 24 days	5 years 2 months 12 days
Range of risk-free rates, minimum	0.50%	0.70%	0.50%	0.70%
Range of risk-free rates, maximum	0.80%	1.10%	0.80%	1.10%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Share-Based Compensation Restricted Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Units granted	75	48	522	453
Weighted average grand date fair value (in dollars per share)	$ 59.43	$ 49.55	$ 59.00	$ 51.59

Share-Based Compensation - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2013 USD ($)
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock option and RSUs	$ 61.1
Weighted-average period expected to be recognized	2 years 10 months 24 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation cost related to unvested stock option and RSUs	$ 47.6
Weighted-average period expected to be recognized	3 years 2 months 24 days

Related Party Transactions - Additional Information (Detail) shares in Millions, $ in Millions	1 Months Ended
	Mar. 31, 2013 USD ($) shares
Related Party Transactions [Abstract]
Number of shares sold in a secondary offering \| shares	5.4
Gross proceeds to selling shareholder	$ 314.4
Expenses in connection with secondary offering	$ 0.5

Segment and Other Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2013 Segment
Segment Reporting [Abstract]
Number of operating business segment	1

Summary of Total Revenues (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Summary of Total Revenues (Detail) - USD ($) $ in Thousands	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenue from External Customer [Line Items]
Product sales, net	$ 206,564	$ 123,002	$ 401,216	$ 224,454
Royalties and contract revenues	1,688	1,229	3,273	2,307
Total revenues	208,252	124,231	404,489	226,761
Xyrem [Member]
Revenue from External Customer [Line Items]
Product sales, net	133,742	89,097	251,268	162,534
Erwinaze And Erwinase [Member]
Revenue from External Customer [Line Items]
Product sales, net	44,860	6,007	86,676	6,007
Prialt [Member]
Revenue from External Customer [Line Items]
Product sales, net	4,694	5,555	9,680	15,077
Psychiatry [Member]
Revenue from External Customer [Line Items]
Product sales, net	11,764	19,789	29,414	37,487
Other [Member]
Revenue from External Customer [Line Items]
Product sales, net	$ 11,504	$ 2,554	$ 24,178	$ 3,349

Summary of Total Revenues Attributed to Geographic Sources (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 208,252	$ 124,231	$ 404,489	$ 226,761
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	191,274	119,440	368,185	215,710
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	13,074	3,172	27,436	9,086
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 3,904	$ 1,619	$ 8,868	$ 1,965

Summary of Revenues from Customers Representing at Least 10% of Total Revenues (Detail) - Sales Revenue, Goods, Net [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Express Scripts [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues	64.00%	69.00%	62.00%	68.00%
Accredo Health Group, Inc. [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenues	18.00%	0.00%	17.00%	0.00%

Total Long-Lived Assets by Location (Detail) - USD ($)
$ in Thousands

Jun. 30, 2013

Dec. 31, 2012

Revenues from External Customers and Long-Lived Assets [Line Items]

Long lived assets

^[1]

$ 10,768

$ 7,281

Ireland [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Long lived assets

3,528

2,437

United States [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Long lived assets

6,895

4,451

Other [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Long lived assets

$ 345

$ 393

[1]	Long-lived assets consist of property and equipment.

Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Restructuring (Details) - USD ($) $ in Thousands	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Restructuring Reserve [Roll Forward]
Balance, beginning of period			$ 1,227
Cash payments			(1,404)
Balance, end of period	$ 1,280		1,280
One-time Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning of period			1,227
Costs incurred during the period			3,834
Cash payments			(1,404)
Balance, end of period	868		868
Selling, general and administrative [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period			1,457
Selling, general and administrative [Member] \| Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Facility Closure Costs	412		412
Selling, general and administrative [Member] \| One-time Termination Benefits [Member]
Restructuring Reserve [Roll Forward]
Costs incurred during the period	$ 100	$ 500	$ 1,045	$ 500

Discontinued Operations (Details)
$ in Thousands

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2012

USD ($)

Jun. 30, 2012

USD ($)

Dec. 31, 2012

women_health_product

Sep. 05, 2012

employee

Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]

Product sales, net

$ 5,308

$ 11,192

Loss from discontinued operations

^[1]

$ (3,968)

$ (6,522)

Women's Health Business [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Women's health products purchased by Meda | women_health_product

The number of employees offered positions by purchaser of the discontinued operation | employee

[1]	There was no income tax on the loss from discontinued operations.

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Taxes [Line Items]
Income tax provision	$ 23,605	$ 6,593	$ 41,239	$ 12,110
Effective income tax rate	35.90%	17.50%	32.50%	16.50%
Ireland [Member]
Income Taxes [Line Items]
Effective statutory income tax rate			12.50%